Lipids, statins and susceptibility to SARS-CoV-2 and influenza A viruses
Melissa Carabott A , Ryan Case A , Sudip Dhakal A and Ian Macreadie A B
+ Author Affiliations
- Author Affiliations
A School of Science, RMIT University, Bundoora, Vic. 3083, Australia
B Tel.: +61 402 564 308; Email: ian.macreadie@rmit.edu.au
Microbiology Australia 42(2) 87-91 https://doi.org/10.1071/MA21021
Submitted: 30 March 2021 Accepted: 26 April 2021 Published: 17 May 2021
Journal Compilation © The Authors 2021 Open Access CC BY, published (by CSIRO Publishing) on behalf of the ASM
Abstract
The extensive and on-going epidemiology studies of the SARS-CoV-2 pandemic have raised interesting observations on statins reducing COVID-19 severity. In this review, literature is analysed to examine how statins affect COVID-19 and influenza A, another pandemic respiratory virus. This information could be useful to prevent or reduce disease severity caused by respiratory viruses.
References
[1] Selleck, P. and Bernard, R. (2020) The 1918 Spanish influenza pandemic: plus ça change, plus c’est la même chose. Microbiol. Aust. 41, 177–182.| The 1918 Spanish influenza pandemic: plus ça change, plus c’est la même chose.Crossref | GoogleScholarGoogle Scholar |
[2] WHO (2021) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (accessed 26 April 2021).
[3] Zeiser, R. (2018) Immune modulatory effects of statins. Immunology 154, 69–75.
| Immune modulatory effects of statins.Crossref | GoogleScholarGoogle Scholar | 29392731PubMed |
[4] Westermeyer, C. and Macreadie, I.G. (2007) Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 7, 436–441.
| Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata.Crossref | GoogleScholarGoogle Scholar | 17257373PubMed |
[5] Kočar, E. et al. (2021) Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications. Biochim. Biophys. Acta (BBA) – Mol. Cell Biol. Lipids 1866, 158849.
| Cholesterol, lipoproteins, and COVID-19: basic concepts and clinical applications.Crossref | GoogleScholarGoogle Scholar |
[6] Sun, X. and Whittaker, G.R. (2003) Role for influenza virus envelope cholesterol in virus entry and infection. J. Virol. 77, 12543.
| Role for influenza virus envelope cholesterol in virus entry and infection.Crossref | GoogleScholarGoogle Scholar | 14610177PubMed |
[7] Louie, A.Y. et al. (2020) Dietary cholesterol affects the pathogenesis of influenza A virus infection in mice. J. Immunol. 204, 93.19.
[8] Bajimaya, S. et al. (2017) Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses. Virology 510, 234–241.
| Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses.Crossref | GoogleScholarGoogle Scholar | 28750327PubMed |
[9] Kow, C.S. and Hasan, S.S. (2020) Meta-analysis of effect of statins in patients with COVID-19. Am. J. Cardiol. 134, 153–155.
| Meta-analysis of effect of statins in patients with COVID-19.Crossref | GoogleScholarGoogle Scholar | 32891399PubMed |
[10] Zhang, X.-J. et al. (2020) In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 32, 176–187.e4.
| In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19.Crossref | GoogleScholarGoogle Scholar | 32592657PubMed |
[11] Torres-Peña, J.D. et al. (2021) Prior treatment with statins is associated with improved outcomes of patients with COVID-19: data from the SEMI-COVID-19 registry. Drugs 81, 685–95.
| 33782908PubMed |
[12] Permana, H. et al. (2021) In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. Pharmacol. Rep. 1–12.
[13] Reiner, Ž. et al. (2020) Statins and the COVID-19 main protease: in silico evidence on direct interaction. AMS 16, 490–496.
| Statins and the COVID-19 main protease: in silico evidence on direct interaction.Crossref | GoogleScholarGoogle Scholar | 32399094PubMed |
[14] Mehrbod, P. et al. (2014) Mechanisms of action and efficacy of statins against influenza. BioMed Res. Int. 2014, 872370.
| Mechanisms of action and efficacy of statins against influenza.Crossref | GoogleScholarGoogle Scholar | 25478576PubMed |
[15] Episcopio, D. et al. (2019) Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus. FASEB J. 33, 9516–9525.
| Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.Crossref | GoogleScholarGoogle Scholar | 31125254PubMed |
[16] Brassard, P. et al. (2017) The effect of statins on influenza-like illness morbidity and mortality. Pharmacoepidemiol. Drug Saf. 26, 63–70.
| The effect of statins on influenza-like illness morbidity and mortality.Crossref | GoogleScholarGoogle Scholar | 27686457PubMed |
[17] Vandermeer, M.L. et al. (2012) Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J. Infect. Dis. 205, 13–19.
| Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.Crossref | GoogleScholarGoogle Scholar | 22170954PubMed |
[18] Frost, F.J. et al. (2007) Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131, 1006–1012.
| Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins.Crossref | GoogleScholarGoogle Scholar | 17426203PubMed |
[19] Musiol, A. et al. (2013) Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation. MBio 4, e00608-13.
| Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation.Crossref | GoogleScholarGoogle Scholar | 24194536PubMed |
[20] Kim, J. and Nam, J.-H. (2020) Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection. Int. J. Obes. 44, 1541–1542.
| Insight into the relationship between obesity-induced low-level chronic inflammation and COVID-19 infection.Crossref | GoogleScholarGoogle Scholar |
[21] Banerjee, M. et al. (2020) Obesity and COVID-19: a fatal alliance. Indian J. Clin. Biochem. 35, 410–417.
| Obesity and COVID-19: a fatal alliance.Crossref | GoogleScholarGoogle Scholar |
[22] Rawat, S.S. et al. (2003) Modulation of entry of enveloped viruses by cholesterol and sphingolipids Mol. Membr. Biol. 20, 243–254.
| Modulation of entry of enveloped viruses by cholesterol and sphingolipidsCrossref | GoogleScholarGoogle Scholar | 12893532PubMed |
[23] Dhakal, S. and Macreadie, I. (2021) Genes of SARS-CoV-2 and emerging variants. Microbiol. Aust. 42, 10–12.
| Genes of SARS-CoV-2 and emerging variants.Crossref | GoogleScholarGoogle Scholar |
[24] Kneller, D.W. et al. (2020) Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat. Commun. 11, 3202.
| Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography.Crossref | GoogleScholarGoogle Scholar | 32581217PubMed |
[25] Dhakal, S. et al. (2019) Simvastatin efficiently reduces levels of Alzheimer’s amyloid beta in yeast. Int. J. Mol. Sci. 20, 3531.
| Simvastatin efficiently reduces levels of Alzheimer’s amyloid beta in yeast.Crossref | GoogleScholarGoogle Scholar |
[26] Wolozin, B. et al. (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 5, 20.
| Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease.Crossref | GoogleScholarGoogle Scholar | 17640385PubMed |
[27] Subir, R. et al. (2020) Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab. Syndr. 14, 1225–1229.
| Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).Crossref | GoogleScholarGoogle Scholar | 32683320PubMed |
[28] Basso, A.D. et al. (2005) The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and tamoxifen anti-tumour activity. J. Biol. Chem. 280, 31101–31108.
| The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling: role in FTI enhancement of taxane and tamoxifen anti-tumour activity.Crossref | GoogleScholarGoogle Scholar | 16006564PubMed |
[29] Rivas, D. et al. (2007) Inhibition of protein farnesylation arrests adipogenesis and affects PPAR gamma expression and activation in differentiating mesenchymal stem cells. PPAR Res. 2007, 81654.
| Inhibition of protein farnesylation arrests adipogenesis and affects PPAR gamma expression and activation in differentiating mesenchymal stem cells.Crossref | GoogleScholarGoogle Scholar | 18274630PubMed |
[30] Liu, Y. et al. (2020) CB-Dock: a web server for cavity detection-guided protein–ligand blind docking. Acta Pharmacol. Sin. 41, 138–144.
| CB-Dock: a web server for cavity detection-guided protein–ligand blind docking.Crossref | GoogleScholarGoogle Scholar | 31263275PubMed |
